Gilead Sciences Inc.
Gilead Sciences Announces Departure of CAO and Interim Replacement
Summary
Gilead Sciences, Inc. announced on March 12, 2025, the departure of Sandra Patterson, the Company's Senior Vice President, Corporate Controller, and Chief Accounting Officer. The Board of Directors has appointed Diane E. Wilfong as the interim Corporate Controller and Chief Accounting Officer, effective immediately. Ms. Wilfong previously held the same position from February 2016 to March 2023 and has extensive experience in similar roles at other companies.
Profitelligence Alerts
Get alerts for GILD
Be first to know when Gilead Sciences Inc. files with the SEC.
Filing Categories
Advertisement
About Gilead Sciences Inc.
Gilead Sciences Inc. is a biopharmaceutical company that focuses on researching, developing, and commercializing innovative medicines in areas of unmet medical need. It is globally recognized for its distinguished work, particularly in the treatment of HIV, liver diseases such as hepatitis B and C, and various forms of cancer. The company's portfolio includes groundbreaking antiviral therapies and a robust pipeline of investigational drugs. Headquartered in Foster City, California, Gilead Sciences Inc. significantly contributes to the healthcare sector by extending the lives of patients with serious illnesses worldwide. Through strategic partnerships and continuous innovation, Gilead remains at the forefront of modern medicine, enhancing its role in the global pharmaceutical market.
Official SEC Documents
Advertisement